Share on

Middle East And Africa Preclinical CRO Market Research Report - Segmented By Service Type, End User & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis, Size, Share, Growth, Trends, & Forecasts (2023 to 2028)

Published: March, 2023
ID: 6470
Pages: 145
Formats: report pdf report excel report power bi report ppt

Middle East & Africa Preclinical CRO Market Size & Growth (2023 to 2028)

As per the research report, the size of the Middle East and Africa Preclinical CRO Market is valued at USD 0.24 billion in 2023 and estimated to be growing at a CAGR of 8.33%, reaching USD 0.36 billion by 2028 during the forecast period 2023 to 2028.

The preclinical CRO market is being driven by the rise of life science businesses in the MEA and the outsourcing of various jobs. In addition, investments in research and development and an increase in public-private collaborations propel the industry forward. Furthermore, the growth of clinical research organizations (CROs) and businesses drives the industry forward. 

The growing usage of preclinical CROs and favorable government policies are boosting the industry. Furthermore, throughout the Middle East and Africa, the low cost of preclinical imaging modalities is a significant driver for the preclinical CRO industry.

The collapse of other testing, like toxicological tests, will be a strong possibility if the preclinical CRO market increases. Furthermore, technical developments in molecular imaging and the tight regulatory framework that governs preclinical research are driving the market.

Preclinical trials, Proof-Of-Concept (POC), and First-In-Human (FIH) studies conducted as multicentre studies can significantly benefit in determining the exact target group and refining recruitment. As a result, preclinical CRO services are critical components of successful drug development that will help meet market demand. Furthermore, the rise of the Middle East and Africa Preclinical CRO business will be driven by technological innovation to provide efficacy and safety in product development.

Furthermore, technical developments have benefited the market in semi-automating or automating current manual procedures. This would boost demand for preclinical CROs, as corporations prefer technological advancements in research studies.

Animal rights activists' prohibitions and limits on animal testing are the main factors limiting the Middle East and Africa market. Animal-based items or treatments, for example, are prohibited in Africa. Furthermore, the surge in alternative approaches such as microdosing is impeding market expansion.

The biggest hurdle for the business is that preclinical CROs do not meet international regulatory criteria such as Good Laboratory Practice (GLP) standards, which leads to quality difficulties.

COVID has had a significant impact on all sectors. During the epidemic, the Middle East and African market suffered some losses. Due to rigorous lockdown requirements, the pharmaceutical and medical device sectors have halted new trials.

This research report on the MEA Preclinical CRO Market has been segmented and sub-segmented into the following categories.

By Service Type:

  • bioanalysis And DMPK Studies
  • Toxicology Testing
  • Other Preclinical Services

By End User:

  • Biopharmaceutical Companies
  • Government and Academic Institutes
  • Medical Device Companies

By Country: 

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

Geographically, the Middle East and Africa preclinical CRO Market is predominantly rising during the forecast period due to the presence of several pharmaceutical enterprises in nations is a significant driver of market expansion. Furthermore, increased R&D spending and solid government regulations propel the Middle East and Africa's preclinical CRO market.

Two primary drivers of European industry growth are the rapid expansion of pharmaceutical enterprises and the rising number of clinical trials. In addition, the entry of significant corporations into the CRO sector propels the industry ahead.

The Saudi Arabia preclinical CRO Market will likely top the Middle East and Africa during the forecasted period. The need for preclinical CRO services will rise as biopharmaceutical companies increase their spending on the development of innovative medications. In addition, biopharmaceutical companies are implementing strategies to remain competitive and agile in the face of evolving knowledge, technological advancements, and an unstable economical environment.

The Israel preclinical CRO Market is predicted to have a significant share of the Middle East and Africa Preclinical CRO Agents market, after Saudi Arabia. Increasing spending on CRO services is likely to significantly fuel market growth throughout the forecast period.

KEY MARKET PLAYERS

Leading companies dominating the MEA Preclinical CRO Market profiled in the report are Charles River Laboratories International, Inc, Laboratory Corporation of America; Pharmaceutical Product Development, LLC.; Wuxi AppTec; Medpace, Inc.; and Paraxel International Corporation., Envigo, Eurofins Scientific; PRA Health Science, Inc.; 

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample